Your Health, We Care

Home > Photo Wall > Honor and qualification

Production approval for Fotivda 1.34mg

Release date: 2024-07-09 16:37:23     Recommended: 103

03L1081_24 替沃扎尼1.34mg 批文_00.jpg

Tivozanib is a novel targeted therapeutic drug primarily used for the treatment of renal cell carcinoma. It belongs to a class of drugs called vascular endothelial growth factor receptor (VEGFR) inhibitors. Tivozanib selectively inhibits the activity of VEGFR, blocks the formation and growth of tumor blood vessels, and thus inhibits tumor progression.

Company News

Research News

Drug news